Stem Cell Research & Therapy · 2021 · 13 citations · 40 references
MedicineOncologyPharmacologyCell TherapyChemotherapyRenal PharmacotherapyAcute Kidney InjuryNephrotoxicity MechanismsRenal ProtectionRenal ToxicityStem Cell MobilizationBone Marrow - Derived CellsBone Marrow-derived Mesenchymal Stromal CellsChemotherapy-associated NephrotoxicityG-csf TherapyGranulocyte Colony-stimulating Factor AdministrationGranulocyte Colony-stimulating Factor MobilizationGranulocyte-macrophage Colony-stimulating Factor MobilizationRenal Function Loss
BACKGROUND: Several studies have confirmed that mobilizing bone marrow-derived stem cells (BMSCs) ameliorates renal function loss following cisplatin-induced acute kidney injury (AKI). The aim of this study was to explore whether the combination of granulocyte-colony stimulating factor (G-CSF) and plerixafor (AMD3100) exerts beneficial effects on renal function recovery in a model of cisplatin-induced nephrotoxicity. METHODS: C57BL/6J mice received intraperitoneal injections of G-CSF (200 μg/kg/day) for 5 consecutive days. On the day of the last injection, the mice received a single subcutaneous dose of AMD3100 (5 mg/kg) 1 h before cisplatin 20 mg/kg injection. Ninety-six hours after cisplatin injection, the mice were euthanized, and blood and tissue samples were collected to assess renal function and tissue damage. Cell mobilization was assessed by flow cytometry (FCM). RESULTS: Mice pretreated with G-CSF/AMD3100 exhibited longer survival and lower serum creatinine and blood urea nitrogen (BUN) levels than mice treated with only G-CSF or saline. Combinatorial G-CSF/AMD3100 treatment attenuated tissue injury and cell death, enhanced cell regeneration, and mobilized a higher number of stem cells in the peripheral blood than G-CSF or saline treatment. Furthermore, the mRNA expression of proinflammatory factors was lower, whereas that of anti-inflammatory factors was higher, in the G-CSF/AMD3100 group than in the G-CSF or saline group (all P < 0.05). CONCLUSIONS: These results suggest that combinatorial G-CSF/AMD3100 therapy mobilizes BMSCs to accelerate improvements in renal functions and prevent cisplatin-induced renal tubular injury. This combinatorial therapy may represent a new therapeutic option for the treatment of AKI and should be further investigated in the future.
40
Human mesenchymal stem cells modulate allogeneic immune cell responses
Sudeepta Aggarwal, Mark F. Pittenger · Blood · 2004 · 4.5K citations · Full text
Incidence and Outcomes in Acute Kidney Injury
Tariq Ali, Izhar Khan, William G. Simpson et al. · Journal of the American Society of Nephrology · 2007 · 828 citations
John F. DiPersio, Edward A. Stadtmauer, Auayporn Nademanee et al. · Blood · 2009 · 780 citations · Full text